Presentation: Medical Devices: how to stay included workshop - Adverse event ...TGA Australia
This presentation discusses adverse event reporting including identification and reporting of adverse events, recognising avoidable errors and the difference in reporting requirements for SAS and clinical trial devices.
SME Assist: Help to navigate the regulatory mazeTGA Australia
Presentation to provide information on TGA’s SME Assist and what the service offers, details on upcoming SME Assist events and information on where to find more help
Presentation: Medical Devices: how to stay included workshop - Annual ReportsTGA Australia
Session 4: Annual Reports: This presentation discusses the requirements and importance of annual reports including information that is required by the TGA and recognising avoidable errors when writing an annual report.
Medical Device Regulation (MDR) overview for Technion, May 25, 2021Levi Shapiro
On May 26, 2021, the EU introduced the most sweeping changes to the Medical Device legal framework since the mid 90's. Ulf Grundmann, Senior Partner, King & Spalding (Frankfurt), reviews some of these regulatory changes, from the perspective of medical device innovators. The presentation includes Scope and Definitions, Classification and Conformity Assessment, Placing a Device on the EU Market, UDI and EUDAMED, Supply Chain Obligations, PMS and Vigilance
Presentation: Medical Devices: how to stay included workshop - Adverse event ...TGA Australia
This presentation discusses adverse event reporting including identification and reporting of adverse events, recognising avoidable errors and the difference in reporting requirements for SAS and clinical trial devices.
SME Assist: Help to navigate the regulatory mazeTGA Australia
Presentation to provide information on TGA’s SME Assist and what the service offers, details on upcoming SME Assist events and information on where to find more help
Presentation: Medical Devices: how to stay included workshop - Annual ReportsTGA Australia
Session 4: Annual Reports: This presentation discusses the requirements and importance of annual reports including information that is required by the TGA and recognising avoidable errors when writing an annual report.
Medical Device Regulation (MDR) overview for Technion, May 25, 2021Levi Shapiro
On May 26, 2021, the EU introduced the most sweeping changes to the Medical Device legal framework since the mid 90's. Ulf Grundmann, Senior Partner, King & Spalding (Frankfurt), reviews some of these regulatory changes, from the perspective of medical device innovators. The presentation includes Scope and Definitions, Classification and Conformity Assessment, Placing a Device on the EU Market, UDI and EUDAMED, Supply Chain Obligations, PMS and Vigilance
Presentation on the background of medicine shortages, definitions, reporting requirements, assessment and management, Section 19A and the compliance framework
Regulatory updates from the TGA Medical Devices Branch - Part 1TGA Australia
Presentation on the review of medicines and medical devices regulation, proposed changes to some definitions and regulation of some products without a medical purpose, reclassification of medical devices (not IVD), Unique Device Identification System and post-market monitoring
This 10-minute lecture gives a step-by-step instruction on medical device definition. It covers the basic definition of a medical device, its key attributes, and intended purpose. A brief insight is provided into in vitro diagnostic medical devices. At the end of this lecture, the student will be able to differentiate a medical device from pharmaceutical and biological healthcare products. The student will also be able to decide whether a particular healthcare product comes under the definition of a medical device.
http://semoegy.com
Regulatory updates from the TGA Medical Devices Branch - Part 2TGA Australia
Presentation on the regulation of software including software as a medical device, proposed regulatory scheme for personalised medical devices, including 3D Printed Devices, proposed changes to the Essential Principles, Conformity Assessment Procedures, and the requirements for devices used in clinical trials, and clarifying the requirements for systems and procedure packs
TGA presentation: AusMedtech, 24 May 2017 TGA Australia
This presentation outlines reforms to the device regulatory system following the Expert Panel Review of Medicines and Medical Devices Regulation, reforms to the in vitro diagnostic devices (IVD) regulatory framework, reforms to the European and IVD system and the TGA's new Clinical Evidence Guidelines.
Complying with Wearable Health Device RegulationTGA Australia
Complying with Wearable Health Device Regulation
• Which devices does the TGA regulate?
• How are devices approved?
• How does the TGA regulate devices once they are on the market?
Presentation: Updates from the Pharmacovigilance and Special Access BranchTGA Australia
This presentation covers using new sources of data in Pharmacovigilance, Pharmacovigilance Inspection Program update, international collaboration activities and Adverse Event Management System.
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
Presentation on the latest on variations, Generic Medicines Reform Program, Human cells and tissue regulation (excluded goods), Faecal Microbiota Transplantation and 2D DataMatrix codes for medicines
Devices Sponsor Information Day: 0 - Developments in medical device regulationTGA Australia
Presentations by TGA and Industry (combined) to help sponsors and manufacturers better understand the regulation of medical devices and in-vitro diagnostic medical devices
Presentation on the background of medicine shortages, definitions, reporting requirements, assessment and management, Section 19A and the compliance framework
Regulatory updates from the TGA Medical Devices Branch - Part 1TGA Australia
Presentation on the review of medicines and medical devices regulation, proposed changes to some definitions and regulation of some products without a medical purpose, reclassification of medical devices (not IVD), Unique Device Identification System and post-market monitoring
This 10-minute lecture gives a step-by-step instruction on medical device definition. It covers the basic definition of a medical device, its key attributes, and intended purpose. A brief insight is provided into in vitro diagnostic medical devices. At the end of this lecture, the student will be able to differentiate a medical device from pharmaceutical and biological healthcare products. The student will also be able to decide whether a particular healthcare product comes under the definition of a medical device.
http://semoegy.com
Regulatory updates from the TGA Medical Devices Branch - Part 2TGA Australia
Presentation on the regulation of software including software as a medical device, proposed regulatory scheme for personalised medical devices, including 3D Printed Devices, proposed changes to the Essential Principles, Conformity Assessment Procedures, and the requirements for devices used in clinical trials, and clarifying the requirements for systems and procedure packs
TGA presentation: AusMedtech, 24 May 2017 TGA Australia
This presentation outlines reforms to the device regulatory system following the Expert Panel Review of Medicines and Medical Devices Regulation, reforms to the in vitro diagnostic devices (IVD) regulatory framework, reforms to the European and IVD system and the TGA's new Clinical Evidence Guidelines.
Complying with Wearable Health Device RegulationTGA Australia
Complying with Wearable Health Device Regulation
• Which devices does the TGA regulate?
• How are devices approved?
• How does the TGA regulate devices once they are on the market?
Presentation: Updates from the Pharmacovigilance and Special Access BranchTGA Australia
This presentation covers using new sources of data in Pharmacovigilance, Pharmacovigilance Inspection Program update, international collaboration activities and Adverse Event Management System.
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
Presentation on the latest on variations, Generic Medicines Reform Program, Human cells and tissue regulation (excluded goods), Faecal Microbiota Transplantation and 2D DataMatrix codes for medicines
Devices Sponsor Information Day: 0 - Developments in medical device regulationTGA Australia
Presentations by TGA and Industry (combined) to help sponsors and manufacturers better understand the regulation of medical devices and in-vitro diagnostic medical devices
The challenges of regulating direct to consumer digital medical devicesTGA Australia
Presentation on digital medical devices, the role of the regulator, challenges in applying the framework to digital devices, international approaches and what is the TGA doing
AzCI presents: Medical Device Regulations through the FDAAnitaBell
Arizona Center for Innovation (AzCI) presents: Working with Your Demographic Market (in orphan drug development)
This presentation is part of a series developed for a workshop on "How to Navigate the Biotech Regulatory Process"
The Arizona Center for Innovation is an incubator and innovation center and provides resources in support of startups getting to the next level and become successful enterprises.
This presentation is an overview of the Medical Device Regulatory Process for China. I used this to teach about SFDA Order No. 27, the amendments, Order No. 15 (Classification), Order No. 16 (Registration), YY, GB, YY/T, GB/T, YZB standards and the different registration forms to use for devices made in People\'s Republic of China, about imported medical devices, and about devices allowed from Taiwan, Hong Kong and Macau regions.
The Therapeutic Goods Administration or TGA is the regulatory body for therapeutic goods in Australia.
The TGA is responsible for conducting assessment and monitoring activities to ensure that therapeutic goods available in Australia are of an acceptable standard.
This report contains an overview of technologies that are able to save human lives, provide early diagnosis of illness and ensure effective treatment. It provides a basic explanation of the classes of medical devices and controlling bodies (FDA, etc.). The presentation also explains the specifics of medical Embedded solutions' testing (on the side of development and testing teams).
This presentation by Volodymyr Palamar (Engineering Manager, Consultant, GlobalLogic Lviv) was delivered at GlobalLogic Lviv Embedded Tech Talk on November 23, 2017.
IPO Fast Forward 2013: Medical Apps Event @ Maidstone & Tunbridge Wells NHS Trust. UK Medical Device regulator presentation from Rob Higgins, MHRA.gov.uk (Reproduced with permission)
A guideline on medical devices designed internationally for harmonization.
As the site access is unavailable have managed the data for easy access of the details for the Regulatory affairs aspirants of Masters of Pharmacy
Pharmacovigilance and complementary medicines - Regulatory requirementsTGA Australia
Presentation on Pharmacovigilance basics – sponsor obligations, Complementary medicine safety – Regulatory perspective and Special considerations for complementary medicine pharmacovigilance
Updates from the Pharmacovigilance and Special Access Branch TGA Australia
Presentation on using new sources of data in Pharmacovigilance, Pharmacovigilance Inspection Program (PVIP) update, International collaboration activities, Adverse Event Management System (AEMS)
Q and A
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...TGA Australia
Presentation on Legislative requirements, specific risks for IMP manufacturing, manufacturing authorisations, PIC/S Guide to GMP PE009-13 and common issues
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
Presentation on the latest on variations, Generic Medicines Reform Program, Human cells and tissue regulation (excluded goods), Faecal Microbiota Transplantation and 2D DataMatrix codes for medicines
This presentation highlights some of the changes in Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TGO 101) Order 2019, compared to the previous Order, Therapeutic Goods Order No. 78 – Standard for tablets and capsules.
Presentation Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TG...TGA Australia
This presentation highlights some of the changes in Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TGO 101) Order 2019, compared to the previous Order, Therapeutic Goods Order No. 78 – Standard for tablets and capsules.
Presentation: Therapeutic Goods Advertising Code (No. 2) 2018TGA Australia
An overview of the Therapeutic Goods Advertising Code (No. 2) 2018 (the Code) followed by a detailed walkthrough of the Code with examples to illustrate the application of the key sections.
Presentation: Advertising therapeutic goods to consumers TGA Australia
An overview of the Therapeutic Goods Advertising Code (No. 2) 2018 (the Code) followed by a detailed walkthrough of the Code with examples to illustrate the application of the key sections.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
1. Navigating regulation
Which devices does the TGA regulate and how do they do it?
Dr Lee Walsh CPEng NER
Senior Engineer, Biomaterials and Engineering Section
Laboratories Branch
Therapeutic Goods Administration
Innovate Health
26 Jun 2018
2. Overview of the TGA
• Part of the Australian Government Department of
Health
• Administers the Therapeutic Goods Act 1989
• Main offices in Canberra – satellite offices in Sydney,
Melbourne, Adelaide and Brisbane
• Operations cost recovered from industry
• Mission: To safeguard and enhance the health of the
Australian community through the effective and timely
regulation of therapeutic goods
Purpose built science and
engineering building
Innovate Health 2018 1
3. Overview of the TGA – What we do
• Evaluate therapeutic goods before they are supplied
• Focus on safety, quality and performance
• Monitor products once they are on the market
• Allow for access to unapproved goods in certain
circumstances
• Provide input to therapeutic goods standards
• We do not make decisions based on value for
money or make decisions about which products
receive Government subsidy
Innovate Health 2018 2
4. Who does this work?
Approximately 750 staff made up of:
Biomedical scientists Engineers Physiotherapists Medical officers
Pharmacists Nurses Toxicologists Lawyers
Cybersecurity Dieticians Scientists Administrative staff
Innovate Health 2018
5. The legislation
The TGA makes decisions based upon:
• Therapeutic Goods Act 1989
• Therapeutic Goods Regulations 1990
• Therapeutic Good (Medical Devices) Regulations 2002
Available on www.legislation.gov.au
Legislative instruments
• Therapeutics Goods Orders (TGO)
• Excluded Goods Orders
• Medical Device Standards Orders (MDSO)
• Conformity Assessment Standards Orders (CASO)
Available on www.tga.gov.au
Innovate Health 2018
6. Is my device regulated by the TGA?
Is it a medical device as defined by the TG Act?
41BD What is a medical device
(1) A medical device is:
(a) any instrument, apparatus, appliance, material or other article (whether used
alone or in combination, and including the software necessary for its proper
application) intended, by the person under whose name it is or is to be
supplied, to be used for human beings for the purpose of one or more of the
following:
(i) diagnosis, prevention, monitoring, treatment or alleviation of disease;
(ii) diagnosis, monitoring, treatment, alleviation of or compensation for an
injury or disability;
(iii) investigation, replacement or modification of the anatomy or of a
physiological process;
(iv) control of conception;
and that does not achieve its principal intended action in or on the human body
by pharmacological, immunological or metabolic means, but that may be
assisted in its function by such means; or
(aa) any instrument, apparatus, appliance, material or other article specified under
subsection (2A); or
(ab) any instrument, apparatus, appliance, material or other article that is included
in a class of instruments, apparatus, appliances, materials or other articles
specified under subsection (2B); or
(b) an accessory to an instrument, apparatus, appliance, material or other article
covered by paragraph (a), (aa) or (ab).
(2) For the purposes of paragraph (1)(a), the purpose for which an instrument, apparatus,
appliance, material or other article (the main equipment) is to be used is to be
ascertained from the information supplied, by the person under whose name the main
equipment is or is to be supplied, on or in any one or more of the following:
(a) the labelling on the main equipment;
(b) the instructions for using the main equipment;
(c) any advertising material relating to the main equipment;
(d) technical documentation describing the mechanism of action of the main
equipment.
(2A) The Secretary may, by notice published in the Gazette or on the Department’s website,
specify a particular instrument, apparatus, appliance, material or other article for the
purposes of paragraph (1)(aa). The notice is not a legislative instrument.
(2B) The Secretary may, by legislative instrument, specify a particular class of instruments,
apparatus, appliances, materials or other articles for the purposes of paragraph (1)(ab).
(3) The Secretary may, by order published in the Gazette or on the Department’s website,
declare that a particular instrument, apparatus, appliance, material or other article, or
that a particular class of instruments, apparatus, appliances, materials or other articles,
are not, for the purposes of this Act, medical devices.
Innovate Health
7. My tech is a medical device, what now?
Australian regulatory guidelines for medical devices (ARGMD)
• Available on www.tga.gov.au
• Currently under review
In summary:
• Australian Register of Therapeutic Goods (ARTG)
• Risk based regulation
• Classification
• Essential Principles
• Quality System
• Evidence
Innovate Health 2018 6
8. Inclusion on the ARTG
In summary:
• Class I – self inclusion
• Higher classes
– Conformity assessment (QMS)
– Submit application
– Selection for audit
• Class III & AIMD
– Design examination (Conformity assessment)
– Unique product identifier
• Contains medicine, animal, human
– Conformity assessment by TGA
Innovate Health 2018 7
9. My device is included in the ARTG, am I done?
Incident Report Investigation Scheme (IRIS)
• Sponsor must report the details of events associated with their devices that have,
or could have resulted in serious injury or death – TG (MD) Regs 2002
Risk assessment
Product improvement
Data logged for ongoing monitoring
Investigation
Regulatory action
Laboratory testing
Referral
Recall Safety alert Report Cancel or suspend
Other action
Innovate Health 2018 8
10. How does TGA assess your evidence
• Expert review
Innovate Health 2018 9
11. Who does this work?
Approximately 750 staff made up of:
Biomedical scientists Engineers Physiotherapists Medical officers
Pharmacists Nurses Toxicologists Lawyers
Cybersecurity Dieticians Scientists Administrative staff
Innovate Health 2018
12. How does TGA assess your evidence
• Expert review
• Against recognised standards and state-of-the-art
• Subject matter expertise
• Best practice (e.g. clinical, software, security)
• But most importantly…
11Innovate Health 2018
13. The Essential Principles
Therapeutic Goods (Medical Devices) Regulations 2002, Schedule 1
• A legislated requirement for medical devices (TG Act 1989, Section 41CA)
• Used in pre-market evaluations
• Used in post market monitoring
• Standards may or may not be sufficient to demonstrate compliance
TGA assessors will assess your device against the Essential Principles
You should assess your device against the Essential Principles
You should consider the Essential Principles at every stage of you medical device’s life
Innovate Health 2018 12
14. The Essential Principles
Therapeutic Goods (Medical Devices) Regulations 2002, Schedule 1
General principles
1. Use of medical devices not to compromise health
and safety
2. Design and construction of medical devices to
conform to safety principles
3. Medical devices to be suitable for intended
purpose
4. Long-term safety
5. Medical devices not to be adversely affected by
transport or storage
6. Benefits of medical devices to outweigh any side
effects
Principles about design and construction
7. Chemical, physical and biological properties
8. Infection and microbial contamination
9. Construction and environmental properties
10. Medical devices with a measuring function
11. Protection against radiation
12. Medical devices connected to or equipped with an energy
source
13. Information to be provided with medical devices
14. Clinical evidence
15. Principles applying to IVD medical devices only
www.legislation.gov.au
Innovate Health 2018 13
15. Common requirements
• Know and understand the Essential Principles
• Quality system – on paper and in practice
• Detailed risk assessments
• Clinical validation
– Evidence that your therapy works and is safe
• Engineering validation
– Evidence that you have designed to the clinical validation
• No verification evidence
– Evidence that you have manufactured what you designed
Innovate Health 2018 14
16. Common mistakes
• Not realising you are regulated
• Lack of familiarity with the Essential Principles
• Ineffective quality system
• Missing evidence (e.g. V&V, clinical, risk)
• Lack of engagement with TGA
Innovate Health 2018 15
17. Remember
• Guidance (http://www.tga.gov.au/)
– ARGMD
– Clinical evidence guidelines
– Conformity assessment guidelines
– Software and ‘apps’
– Standards orders
• You can talk to us
– Premarket – 1800 141 144 or devices@tga.gov.au
– Postmarket – 1800 809 361 or iris@tga.gov.au
– Conferences
– Your investigators and assessors
• TGA administers the legislation
• and…
Innovate Health 2018 16
18. Remember
Essential Principles
General principles
1. Use of medical devices not to compromise health
and safety
2. Design and construction of medical devices to
conform to safety principles
3. Medical devices to be suitable for intended
purpose
4. Long-term safety
5. Medical devices not to be adversely affected by
transport or storage
6. Benefits of medical devices to outweigh any side
effects
Principles about design and construction
7. Chemical, physical and biological properties
8. Infection and microbial contamination
9. Construction and environmental properties
10. Medical devices with a measuring function
11. Protection against radiation
12. Medical devices connected to or equipped with an energy
source
13. Information to be provided with medical devices
14. Clinical evidence
15. Principles applying to IVD medical devices only
Innovate Health 2018 17